Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | IDH2 | P48735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102644 | 0.74 | GPBAR1 (0.42) | GRM1GPBAR1GAAPOLBL3MBTL1 | |
| SCHEMBL13005241 | 0.71 | GPBAR1 (0.40) | GRM1GPBAR1GAAPOLBL3MBTL1 | |
| SCHEMBL10102638 | 0.67 | GPBAR1 (0.42) | GRM1GPBAR1 | |
| SCHEMBL10102640 | 0.66 | HRH4 (0.41) | GRM1GPBAR1 | |
| SCHEMBL4743270 | 0.62 | GPBAR1 (0.64) | GRM1GPBAR1TOP1 | |
| SCHEMBL10102661 | 0.61 | GPBAR1 (0.41) | GRM1GPBAR1 | |
| SCHEMBL10102671 | 0.61 | DHODH (0.46) | — | |
| SCHEMBL10102660 | 0.60 | IDO1 (0.44) | GRM1GPBAR1 | |
| SCHEMBL4739220 | 0.60 | GPBAR1 (0.62) | GPBAR1TOP1 | |
| SCHEMBL3383001 | 0.59 | DHODH (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | KIF5A, KIF5C, KIF5B | GRM1 477/4885GPBAR1 2259/4885GAA 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.